Alkem Laboratories · ALKEM
Alkem trims its India and US growth guidance as its Daman plant waits for the FDA
Quarterly sales rose 13.8%, but management lowered its India and US growth outlook, gave Enzene's break-even a longer date and kept a margin guide that a weaker second half already tests.
3 min read Published on
Published by
Inve Content team
Alkem Laboratories reported on 12 November that sales in the September 2026 quarter rose 13.8% from a year earlier, with EBITDA, its profit before depreciation, interest, tax and other income, up a little less. On the same day management lowered what it expects this year from its two biggest drug markets. Sandeep Singh, the managing director, put growth in India, the company's largest business, a point below where he had put it in August: "I think we will end up by around close to 11% of India growth overall."
Alkem cut its India growth guide by a point in the twelve weeks since August
%
India sales growth guide for FY27
- 12% Given 20 Aug
- 11% Given 12 Nov
The American outlook came down as well. Mr Singh now expects mid-single-digit growth for the year, measured in constant currency, that is, before any gain from exchange rates. In August he had spoken of growth of high single digits to mid, adding that currency would help.
The reason is a factory. Alkem's plant at Daman, on India's west coast, supplied almost half of its US revenue by the company's account in August, and its standing with the US Food and Drug Administration bars new approvals from the site. Three products the company had lined up for launch are waiting. In August management hoped to settle the matter within a year at most. Every response has now been sent, said Amrut Naik, who took over as chief executive of the pharmaceutical business the day before the results: "We are, in fact, waiting for their counter responses in terms of how and when they will come for a reaudit."
The newer businesses have slipped too. In August Alkem said Enzene, its biologics and contract-manufacturing arm, would break even at its US contract plant within four to five quarters. Now an executive put break-even for Enzene as a whole at a year and a half to two years at most, though August's date covered only the US plant. The US application for denosumab, a copy of a bone drug that the company aimed in February to launch by the end of this year, now has to be filed again. Asked about Enzene's hits and misses, Mr Singh listed three and said: "But if I have to pick one, I think it's the BLA disappointment."
Against these trims, the margin looks like spare room. In May the company guided to an EBITDA margin of 20% to 21% for the year, and the first half finished above that range. Management declined to raise it, calling a revision premature, and Mr Singh said the full year might at best match last year's margin, with pressure in the third and fourth quarters. The first half, though, was below the same half a year earlier, and in each of the past two years Alkem's second half has been its weaker one: last year it ran well under the full-year figure. By our arithmetic, if second-half sales match the first half's, matching last year's full-year margin would take a second-half margin of about 19.2%, against 18.3% a year earlier, which is what management's forecast implies.
This year's first-half margin beats the guide but trails last year's; the past two second halves were weaker
%
EBITDA margin
- 22.5% H1 FY26
- 18.3% H2 FY26
- 20.4% FY26
- 21.6% H1 FY27
Below EBITDA, the quarter went the other way. Pre-tax profit grew but net profit fell, because the tax rate jumped from a year earlier, when Alkem was still paying the minimum alternate tax, which management said a year ago it would leave once the financial year to March ended. The first-half rate sat above the band the company gave in August. Asked whether the higher depreciation and interest, partly from buying Occlutech, the heart-device maker, were the new norm, an executive said they were.
Tax turned a rise in pre-tax profit into a fall in net profit last quarter
₹ cr
Profit before tax
- ₹896 crore Q2 FY26
- ₹1,000 crore Q2 FY27
Net profit
- ₹779 crore Q2 FY26
- ₹667 crore Q2 FY27
Mr Naik, whose commercial career was spent largely in overseas markets, said he expects to have a clearer view of the path he wants to take in three to four months.
Alkem Laboratories stock page →
The record: full financial tables
Financials
Income statement, last 8 quarters
| Quarter end | Sales | YoY | Operating profit | Op. margin | Other income | PBT | Net profit |
|---|---|---|---|---|---|---|---|
| Sept 2026 | 4,552 | +13.8% | 1,025 | 22.5% | 169 | 1,000 | 667 |
| Jun 2026 | 3,740 | +10.9% | 766 | 20.5% | 153 | 772 | 521 |
| Mar 2026 | 3,603 | +14.6% | 517 | 14.3% | 65 | 423 | 251 |
| Dec 2025 | 3,737 | +10.8% | 828 | 22.2% | 90 | 781 | 653 |
| Sept 2025 | 4,001 | +17.2% | 921 | 23.0% | 104 | 896 | 779 |
| Jun 2025 | 3,371 | +11.2% | 739 | 21.9% | 149 | 771 | 668 |
| Mar 2025 | 3,144 | +7.1% | 391 | 12.4% | 146 | 396 | 322 |
| Dec 2024 | 3,374 | +1.5% | 759 | 22.5% | 93 | 731 | 641 |
Balance sheet
| As of | Equity | Debt | Investments | Fixed assets | CWIP | Total assets |
|---|---|---|---|---|---|---|
| Sept 2026 | 14,865 | 2,310 | 2,073 | 5,878 | 161 | 23,060 |
| Mar 2026 | 13,820 | 2,047 | 1,869 | 3,871 | 282 | 20,858 |
| Sept 2025 | 13,346 | 2,356 | 2,533 | 3,319 | 653 | 20,287 |
| Mar 2025 | 11,985 | 1,381 | 1,846 | 2,852 | 548 | 17,691 |
Cash flow
| Year end | Operating | Investing | Financing | Free cash flow |
|---|---|---|---|---|
| Mar 2026 | 1,963 | −1,682 | −503 | 1,476 |
| Mar 2025 | 1,913 | −1,288 | −811 | 1,278 |
| Mar 2024 | 1,948 | −1,011 | −1,145 | 1,761 |
| Mar 2023 | 1,682 | 120 | −1,761 | 1,453 |